BIOCOVAX for the prophylaxis of Covid-19

Biomed’s strategy is to provide prevention and drug treatment in oral formulations to anyone who is at risks (such as healthcare providers, first responders) or patients in early onset of Covid-19 with the physician prescription.

Oral Polio Vaccine for the prevention of Covid-19

Thanks to the polio vaccines, poliomyelitis has been eradicated globally, except Afghanistan and Pakistan are the only two countries where the disease is still classified as endemic continents. Prevention of polio disease spread has been accomplished by vaccination. There are two kinds of polio vaccine—oral polio vaccine (OPV), which uses weakened poliovirus, and inactivated polio vaccine (IPV), which is injected. The OPV is less expensive and easier to administer, and can spread immunity beyond the person vaccinated, creating contact immunity.

Oral polio vaccine has been approved by the FDA and more than 100 countries worldwide.

More than 1 billion people were vaccinated with OPV and effectiveness is 98%.

Vaccination for poliomyelitis is part of routine childhood vaccination. Either oral polio vaccine (OPV) or inactivated polio vaccine (IPV) have been administered in childhood inducing an immunity which, although protective for years, wans over time and is, for the most part, undetectable in adults unless a booster is administered. United States residents are advised to receive a booster prior to travelling to countries where polio disease remains endemic.

It has been found that an oral polio vaccine can be used as a prophylaxis early onset of Covid-19, because both poliovirus and coronavirus are positive-strand RNA viruses; therefore, they may induce and be affected by common innate immunity mechanisms.

Oral polio attenuated vaccines is more effective than IPV to fight against RNA viruses (including Poliovirus and coronavirus) inducing an immune response that recognizes the non-structural antigens of the viral particle. There is extensive homology between Poliovirus and SARS-CoV-2 RNA-dependent-RNA-polymerase (RdRp) both within the coding regions and illustrated in the 3-dimensional modeling. The homology between the viral epitopes may be sufficient such that adults who receive a polio booster develop an immune response that cross-reacts with SARS-CoV-2.

As a result, oral polio vaccine provides a powerful stimulant of an immediate, emergency response from the innate immune system against a wide range of other viruses including Covid-19.

One risk of using an oral polio vaccine is a potential rare side effect caused by vaccine-associated paralytic polio. The incidence was about 1 per million vaccinated children. The potential risks to adults would be extremely rare.

BioCovax™ is an oral polio vaccine which was formulated to be used in combination with Traneurocin, a neuroprotective agent.

Clinical trials results have demonstrated that NA-831 or Traneurocin, a neuroprotective drug can be administered orally in conjunction with oral polio vaccine to mitigate any potential risks of vaccine-associated paralytic polio.

BioCovax™ is an oral polio vaccine formulation which can be used as a prophylaxis for early onset of Covid-19 in adults.